Evidence map›Paper›PMID 40688843›Full record

ArticleCureus2025

Integration of Hematologic and Metabolic Biomarkers for Outcome Prediction in Acute Coronary Syndromes Without ST Elevation.

Emir Becirovic, Minela Becirovic, Kenana Ljuca, Amir Becirovic, Mirza Babic, Nadina Ljuca, Zarina Babic Jusic, Emir Begagic, Elma Mujakovic, Anesa Terzic

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emir BecirovicInternal Medicine Clinic, University Clinical Centre Tuzla, Tuzla, BIH.
Minela BecirovicInternal Medicine Clinic, University Clinical Centre Tuzla, Tuzla, BIH.
Kenana LjucaGynecology and Obstetrics, University Clinical Centre Ljubljana, Ljubljana, SVN.
Amir BecirovicEndocrinology, University Clinical Centre Tuzla, Tuzla, BIH.
Mirza BabicInternal Medicine, Cantonal Hospital Bihać, Bihać, BIH.
Nadina LjucaMedicine, University of Tuzla, Tuzla, BIH.
Zarina Babic JusicRadiology, Cantonal Hospital Bihać, Bihać, BIH.
Emir BegagicGeneral Medicine, School of Medicine, University of Zenica, Zenica, BIH.
Elma MujakovicAnatomy, Faculty of Medicine, University of Tuzla, Tuzla, BIH.
Anesa TerzicGeneral Medicine, Health Center Gračanica, Gračanica, BIH.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Non-ST-elevation myocardial infarction (NSTEMI) represents a prevalent form of acute coronary syndrome associated with substantial early risk of adverse outcomes. Inflammatory and metabolic disturbances are increasingly recognized as key contributors to the disease. Hematologic indices such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV), along with the triglyceride-glucose index adjusted for BMI (TyG-BMI), have emerged as promising prognostic markers. However, their dynamic behavior in early NSTEMI remains insufficiently explored. Materials and methods This prospective study included 170 patients hospitalized for NSTEMI at the University Clinical Centre Tuzla between February 2022 and January 2023. Hematologic and metabolic indices were calculated at admission and repeated 24 hours later. Patients were followed for three months to document major adverse cardiovascular events (MACE), including cardiovascular death, reinfarction, and urgent revascularization. The median age was 67 years, and 60.6% of patients were male. Hypertension, hyperlipidemia, and diabetes mellitus were the most common comorbidities. Results Significant 24-hour reductions were observed in NLR, PLR, SII, SIRI, and PIV (all p < 0.01), while C-reactive protein (CRP) levels more than doubled (p < 0.001). Patients who developed MACE showed persistently elevated inflammatory indices and smaller declines in PIV and SIRI. Change in SIRI (ΔSIRI) demonstrated the strongest predictive value (AUC = 0.63), followed by SII and TyG-BMI. Notably, reduced resolution of PIV and persistently elevated TyG-BMI were significantly associated with adverse outcomes. Overall, MACE occurred in 51.2% of patients, including a 14.7% mortality rate. Conclusion Early changes in systemic inflammation and metabolic stress, particularly SIRI and TyG-BMI dynamics, offer valuable prognostic insight and may enhance early risk stratification in NSTEMI patients.

Indexed as

inflammationmacenstemipivprognostic biomarkerssirityg-bmi

Identifiers

PMID40688843
PMCPMC12276801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.